Physician profile
Ruth L Eckert
NPI 1376571174
$793.88
in general payments reported to CMS, 2019-2025
14 companies · $71.49 in 2025
The $71.49 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $48.17 · 2022: $282 · 2023: $159 · 2024: $72.29 · 2025: $71.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $365.81 | 2019-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $117.90 | 2019-2022 | |
| Biosense Webster, INC. | $79.99 | 2019 | |
| Exact Sciences Corporation | $44.31 | 2024-2025 | Cologuard Collection Kit |
| Abiomed | $32.47 | 2020 | |
| Axonics, INC. | $25.94 | 2023 | Axonics |
| Abbvie INC. | $18.88 | 2022 | |
| Novo Nordisk INC | $18.53 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $18.20 | 2022 | |
| Sanofi Pasteur INC. | $17.45 | 2019 | |
| Allergan, INC. | $15.70 | 2020 | |
| Amgen INC. | $14.22 | 2024 | Repatha |
| Merck Sharp & Dohme LLC | $13.65 | 2019 | |
| Avanir Pharmaceuticals, INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Eckert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.